Clinical trial
A Phase 2 Multicenter Single Arm Clinical Trial of ABX-EGF Monotherapy in Subjects With Metastatic Colorectal Cancer Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy
NCT00083616 is registered in ClinicalTrials.gov with Amgen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Multicenter Single Arm Clinical Trial of ABX-EGF Monotherapy in Subjects With Metastatic Colorectal Cancer Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy
- Lead sponsor
- Amgen
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 31, 2004
- Completion date
- December 31, 2008
- Enrollment
- 185 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
colorectal cancer, metastatic cancer